Company: ABBV
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001551152-25-000040
Chunk: 29

Company: AbbVie Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 29
---
$2,719 Weighted-average shares of common stock outstanding1,768 1,768 1,768 1,769 Effect of dilutive securities3 3 4 3 Weighted-average diluted shares outstanding1,771 1,771 1,772 1,772 Diluted earnings per share attributable to AbbVie Inc.$0.52 $0.77 $1.24 $1.53 Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

Note 4 Licensing, Acquisitions and Other Arrangements 

Proposed Acquisition of Capstan Therapeutics, Inc. In June 2025, AbbVie entered into a definitive agreement to acquire Capstan Therapeutics, Inc. (Capstan), including its lead program CPTX2309, a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate, currently in Phase 1, for the treatment of B cell-mediated autoimmune diseases. Under the terms of the agreement, AbbVie will make an upfront cash payment of approximately $2.1 billion to acquire Capstan. The transaction is expected to close in 2025, subject to regulatory approvals and other customary closing conditions.

2025 Form 10-Q | 7

Acquisition of Nimble Therapeutics, Inc.On January 23, 2025, AbbVie completed its acquisition of Nimble Therapeutics, Inc. (Nimble). Nimble is a biotechnology company dedicated to delivering on the promise of oral peptide therapeutics and its lead asset, an investigational oral peptide IL23R inhibitor, is in preclinical development for the treatment of psoriasis. The aggregate purchase price of $288 million was comprised of a $210 million upfront cash payment and $78 million for the acquisition date fair value of contingent consideration liabilities, for which AbbVie may owe up to $130 million in future payments upon achievement of certain development milestones. The transaction was accounted for as a business combination using the acquisition method of accounting. As of the acquisition date, AbbVie acquired $118 million of intangible assets and resulted in the recognition of $170 million of goodwill. Goodwill was calculated as the excess of the consideration transferred over the fair value of net assets recognized and represents the future economic benefits arising from other assets acquired that could not be